Clinical study 2023
“... 2% taurolidine lock was completely safe and highly effective in the treatment of both catheter-colonization and catheter-related bloodstream infection in cancer patients with totally implanted venous access devices.”
Brescia et al. J Vasc Access 2023. DOI: 10.1177/11297298211026453
Clinical study 2018
“Overall, taurolidine [2 %] reduced the risk for CRBSIs by more than four times. Given its favourable safety and cost profile, taurolidine locking should be considered as an additional strategy to prevent CRBSIs.”
Wouters et al. Aliment Pharmacol Ther 2018. DOI: 10.1111/apt.14904
Clinical study 2014
“... data strongly suggest that taurolidine [2 %] decreases catheter-related bloodstream infections and occlusions in HPN [home parenteral nutrition] patients compared with heparin.”
Olthof et al. PLoS One 2014. DOI: 10.1371/journal.pone.0111216
Clinical study 2010
“Taurolidine [2 %] lock dramatically decreased catheter-related bloodstream infections when compared with heparin in this high-risk group of Home Parenteral Nutrition patients.”
Blisseling et al. Clin Nutr 2010. DOI: 10.1016/j.clnu.2009.12.005
